Pieralice Silvia, Pozzilli Paolo
Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy.
Centre of Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK.
Diabetes Metab J. 2018 Dec;42(6):451-464. doi: 10.4093/dmj.2018.0190.
Latent autoimmune diabetes in adults (LADA) is a heterogeneous disease characterized by a less intensive autoimmune process and a broad clinical phenotype compared to classical type 1 diabetes mellitus (T1DM), sharing features with both type 2 diabetes mellitus (T2DM) and T1DM. Since patients affected by LADA are initially insulin independent and recognizable only by testing for islet-cell autoantibodies, it could be difficult to identify LADA in clinical setting and a high misdiagnosis rate still remains among patients with T2DM. Ideally, islet-cell autoantibodies screening should be performed in subjects with newly diagnosed T2DM, ensuring a closer monitoring of those resulted positive and avoiding treatment of hyperglycaemia which might increase the rate of β-cells loss. Thus, since the autoimmune process in LADA seems to be slower than in classical T1DM, there is a wider window for new therapeutic interventions that may slow down β-cell failure. This review summarizes the current understanding of LADA, by evaluating data from most recent studies, the actual gaps in diagnosis and management. Finally, we critically highlight and discuss novel findings and future perspectives on the therapeutic approach in LADA.
成人隐匿性自身免疫性糖尿病(LADA)是一种异质性疾病,其特征是与经典1型糖尿病(T1DM)相比,自身免疫过程强度较低,临床表型广泛,兼具2型糖尿病(T2DM)和T1DM的特征。由于LADA患者最初不依赖胰岛素,只有通过检测胰岛细胞自身抗体才能识别,因此在临床环境中可能难以识别LADA,T2DM患者中的误诊率仍然很高。理想情况下,应在新诊断的T2DM患者中进行胰岛细胞自身抗体筛查,确保对检测结果呈阳性的患者进行更密切的监测,并避免对可能增加β细胞丢失率的高血糖症进行治疗。因此,由于LADA中的自身免疫过程似乎比经典T1DM中的慢,所以有更广泛的窗口来进行可能减缓β细胞衰竭的新治疗干预。本综述通过评估最新研究的数据、诊断和管理方面的实际差距,总结了目前对LADA的认识。最后,我们批判性地强调并讨论了LADA治疗方法的新发现和未来前景。